Ten HIV care and treatment sites in Rwanda participate in CA-IeDEA, including 11 public health facilities and one non-governmental health center. The IeDEA Rwanda cohort includes approximately 28,000 adult and pediatric patients, including more than 14,000 patients who are currently in care.

Work in IeDEA Rwanda is focused on the following research priorities:

  • Exploring pregnancy outcomes in the Option B/B+ era and long-term clinical outcomes among HIV-exposed uninfected children.
  • Exploring patient- and health center-level predictors of ART initiation, loss to follow-up and viral suppression under “Treat All” guidelines.
  • Assessing changes in renal function among HIV infected adults receiving Tenofovir Disoproxil Fumarate (TDF)-based first-line therapy, the incidence of TDF-induced renal toxicity, and predictors of TDF-induced renal toxicity among HIV infected adults
  • Assessing trends in HPV prevalence among HIV+ Rwandan women and assessing the immune response (CD4 cell count) among HIV+ women.

IeDEA’s research in Rwanda is led by principal investigator, Gad Murenzi, of the Rwanda Military Hospital.